SpringWorks Therapeutics (SWTX) has agreed to be acquired by German technology firm Merck KGaA for $47 per share in cash, the companies said in a joint statement Monday.
The consideration represents about $3.9 billion in equity value, or $3.4 billion in enterprise value, for SprinWorks.
The deal is expected to close in H2, subject to regulatory approvals and customary closing conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.